JP2024535431A5 - - Google Patents

Info

Publication number
JP2024535431A5
JP2024535431A5 JP2024519055A JP2024519055A JP2024535431A5 JP 2024535431 A5 JP2024535431 A5 JP 2024535431A5 JP 2024519055 A JP2024519055 A JP 2024519055A JP 2024519055 A JP2024519055 A JP 2024519055A JP 2024535431 A5 JP2024535431 A5 JP 2024535431A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
scaffold
sequence number
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535431A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077182 external-priority patent/WO2023056297A1/en
Publication of JP2024535431A publication Critical patent/JP2024535431A/ja
Publication of JP2024535431A5 publication Critical patent/JP2024535431A5/ja
Pending legal-status Critical Current

Links

JP2024519055A 2021-09-28 2022-09-28 シェーグレン症候群の治療及び予防におけるcd40l特異的tn3由来足場 Pending JP2024535431A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163249553P 2021-09-28 2021-09-28
US63/249,553 2021-09-28
US202263375282P 2022-09-12 2022-09-12
US63/375,282 2022-09-12
PCT/US2022/077182 WO2023056297A1 (en) 2021-09-28 2022-09-28 Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome

Publications (2)

Publication Number Publication Date
JP2024535431A JP2024535431A (ja) 2024-09-30
JP2024535431A5 true JP2024535431A5 (cg-RX-API-DMAC7.html) 2025-10-07

Family

ID=84360925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519055A Pending JP2024535431A (ja) 2021-09-28 2022-09-28 シェーグレン症候群の治療及び予防におけるcd40l特異的tn3由来足場

Country Status (11)

Country Link
US (2) US20240383991A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408455A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024535431A (cg-RX-API-DMAC7.html)
KR (1) KR20240101563A9 (cg-RX-API-DMAC7.html)
AU (1) AU2022358509A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230926A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024000881A1 (cg-RX-API-DMAC7.html)
IL (1) IL311710A (cg-RX-API-DMAC7.html)
MA (1) MA65537A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003954A (cg-RX-API-DMAC7.html)
WO (1) WO2023056297A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260217842A1 (en) * 2023-01-13 2026-07-30 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome
KR20250162587A (ko) * 2023-03-28 2025-11-18 비엘라 바이오, 인크. 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3704158A1 (en) * 2017-11-03 2020-09-09 Novartis AG Anti-cd40 antibodies for use in treatment of sjögren's syndrome
KR102919125B1 (ko) * 2018-09-26 2026-01-27 비엘라 바이오, 인크. Cd40l 길항제 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2023052458A5 (cg-RX-API-DMAC7.html)
JP2022538237A5 (cg-RX-API-DMAC7.html)
HUP0301444A2 (hu) Ribavirin és pegilezett alfa-interferon alkalmazása HCV fertőzés kezelésére szolgáló gyógyszerkészítmény előállítására
WO1998005350A1 (en) Materials and methods for treatment of plaquing diseases
CN116390712A (zh) 治疗偏头痛
CN101878037A (zh) 能够中和乙型肝炎病毒的人抗体在预防或治疗乙型肝炎病毒感染中的用途
EP0230574A2 (en) Pharmaceutical compositions against infections caused by LAV/HTLV III virus and the use thereof
JP2023531682A (ja) D型肝炎ウイルス感染の処置のための組成物および方法
EP4584295A1 (en) Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
JPH11501310A (ja) レトロウイルスの調節タンパク質から誘導された無毒の免疫原、抗体、製造方法およびそれらを含んでなる医薬組成物
KR20110053327A (ko) 텔라프레비르 투여 방식
JP2022514561A5 (cg-RX-API-DMAC7.html)
TW202417015A (zh) 以非妥西蘭治療血友病
AU2021382954B2 (en) Pharmaceutical composition, pharmaceutical combined formulation, and combined formulation kit for prevention or treatment of chronic hepatitis b, each comprising, as active ingredient, oral antiviral agent and therapeutic vaccine including lipopeptide and poly(i:c) adjuvant
JP2024540294A5 (cg-RX-API-DMAC7.html)
JP2022513438A5 (cg-RX-API-DMAC7.html)
CN119923262A (zh) 在儿科患者中用卡替拉韦和利匹韦林治疗hiv的方法
JP2000007578A (ja) C型肝炎ウイルスの陰性化のための投薬システム
JP2770911B2 (ja) 抗ウイルス医薬組成物
CN101282741A (zh) 治疗或预防缺血性再灌注损伤或多器官衰竭的方法
JP7619659B2 (ja) コロナウイルス感染症を治療又は予防する方法及び組成物
JP2002500175A (ja) ヒト免疫不全ウイルスに対して使用する多分枝ペプチド構築物含有リポソーム
Longhurst et al. In vivo CRISPR/Cas9 editing of KLKB1 in patients with HAE
AU2025205863A1 (en) Lutikizumab for use in a treatment of hidradenitis suppurativa
JP2006515011A (ja) Hcv併用療法